InsidersTradesSigma
Total declarations
Companies
▲ Purchases (5 ops.)
▼ Sales (0 ops.)
Insider track record
Board DirectorDisclosed buys
5
Disclosed sells
0
T+90 hit rate
75%
T+90 mean return
+16.9%
Across 8 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Browse the full record of transactions filed by Davis Todd C, Director. Officer active across 5 companies, notably Ligand Pharmaceuticals INC. Cumulatively, 28 disclosures have been logged. Split: 5 buys · 0 sell. Total volume traded: €602k. History available since 4 June 2021. The latest transaction was filed on 30 June 2026 (J). Regulator: SEC (Form 4). The full history is accessible without signup.
Declarations28 total
132 shares@ US$160.70950.0003% mcap1.7% of flowCommon StockSEC:0002001011-26-000106:0
35,445 sharesCommon StockSEC:0001919246-26-000088:0
Ideal exit: 8 Mar 2027 (T+270)
503 sharesCommon StockSEC:0001919246-26-000088:1
Ideal exit: 8 Mar 2027 (T+270)
12,900 shares0Common StockSEC:0001919246-26-000046:0
4,961 shares0Common StockSEC:0001919246-26-000046:1
19,108 shares0Common StockSEC:0001919246-26-000046:2
10,495 shares0Common StockSEC:0002001011-26-000033:0
1,500,000 shares@ US$10.00Common StockSEC:0001753926-25-001075:0
233 shares@ US$91.07751.6% of flowCommon StockSEC:0002001011-25-000050:0
1,680 shares@ US$104.5714.7% of flowCommon StockSEC:0002001011-25-000029:0
Ideal exit: 3 Feb 2026 (T+270)
21,382 shares0Common StockSEC:0002001011-25-000014:0
20,784 shares0Common StockSEC:0002001011-25-000013:0
2,500 shares@ US$97.392220.9% of flowCommon StockSEC:0002001011-24-000067:0
Ideal exit: 5 May 2025 (T+270)
350 shares@ US$60.7071.9% of flowCommon StockSEC:0002001011-24-000062:0
7,448 shares@ US$46.2029.9% of flowCommon StockSEC:0002001011-24-000035:0
32,436 shares0Common StockSEC:0002001011-24-000027:0
29,167 shares@ US$4.80100.0% of flowCommon StockSEC:0001753926-24-000374:0
1,381 shares@ US$74.659.0% of flowCommon StockSEC:0002001011-24-000016:0
4,000 shares@ US$59.382288.6% of flowCommon StockSEC:0000886163-23-000057:0
Ideal exit: 18 Jun 2024 (T+270)
420 shares@ US$73.762.7% of flowCommon StockSEC:0000886163-23-000038:0
17,005 shares0Common StockSEC:0000899243-23-006294:0
7,375 shares0Common StockSEC:0001437749-22-019437:0
1,004 shares0Common StockSEC:0000886163-22-000082:0
252,207 shares0Common StockSEC:0001103021-22-000066:0
7,684 shares0Common StockSEC:0001103021-22-000027:0
25 of 28 declarations
About Davis Todd C
Todd C. Davis is a Board Member of Ligand Pharmaceuticals Inc., BioDelivery Sciences International Inc., and Vaxart, Inc. He brings expertise in biopharmaceuticals and drug development. His role involves guiding the strategic initiatives of these innovative companies.
